Trevi Therapeutics Statistics
Total Valuation
TRVI has a market cap or net worth of $1.92 billion. The enterprise value is $1.75 billion.
| Market Cap | 1.92B |
| Enterprise Value | 1.75B |
Important Dates
The last earnings date was Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TRVI has 141.98 million shares outstanding. The number of shares has increased by 33.10% in one year.
| Current Share Class | 141.98M |
| Shares Outstanding | 141.98M |
| Shares Change (YoY) | +33.10% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 0.70% |
| Owned by Institutions (%) | 80.07% |
| Float | 117.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 10.07 |
| P/TBV Ratio | 11.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.75, with a Debt / Equity ratio of 0.00.
| Current Ratio | 24.75 |
| Quick Ratio | 24.30 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -33.59% and return on invested capital (ROIC) is -24.14%.
| Return on Equity (ROE) | -33.59% |
| Return on Assets (ROA) | -23.01% |
| Return on Invested Capital (ROIC) | -24.14% |
| Return on Capital Employed (ROCE) | -30.59% |
| Weighted Average Cost of Capital (WACC) | 10.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.34M |
| Employee Count | 34 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -73,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +91.22% in the last 52 weeks. The beta is 1.05, so TRVI's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | +91.22% |
| 50-Day Moving Average | 13.84 |
| 200-Day Moving Average | 11.53 |
| Relative Strength Index (RSI) | 44.97 |
| Average Volume (20 Days) | 1,080,340 |
Short Selling Information
The latest short interest is 13.29 million, so 9.36% of the outstanding shares have been sold short.
| Short Interest | 13.29M |
| Short Previous Month | 15.29M |
| Short % of Shares Out | 9.36% |
| Short % of Float | 11.28% |
| Short Ratio (days to cover) | 7.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -52.77M |
| Pretax Income | -45.68M |
| Net Income | -45.61M |
| EBITDA | -52.63M |
| EBIT | -52.77M |
| Earnings Per Share (EPS) | -$0.32 |
Balance Sheet
The company has $171.78 million in cash and $682,000 in debt, with a net cash position of $171.10 million or $1.21 per share.
| Cash & Cash Equivalents | 171.78M |
| Total Debt | 682,000 |
| Net Cash | 171.10M |
| Net Cash Per Share | $1.21 |
| Equity (Book Value) | 172.13M |
| Book Value Per Share | 1.34 |
| Working Capital | 169.01M |
Cash Flow
In the last 12 months, operating cash flow was -$45.30 million and capital expenditures -$114,000, giving a free cash flow of -$45.42 million.
| Operating Cash Flow | -45.30M |
| Capital Expenditures | -114,000 |
| Depreciation & Amortization | 141,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -45.42M |
| FCF Per Share | -$0.32 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TRVI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.10% |
| Shareholder Yield | -33.10% |
| Earnings Yield | -2.38% |
| FCF Yield | -2.37% |
Analyst Forecast
The average price target for TRVI is $23.90, which is 77.04% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $23.90 |
| Price Target Difference | 77.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |